Overview

The Use of HEMOBAG to Salvage Blood After Cardiac Surgery

Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The avoidance of blood transfusions benefits the patient. Cardiopulmonary bypass (CPB) is routinely used in complex cardiac surgeries. This device requires circulating blood through an oxygenator and pump while the heart is stopped. Upon discontinuation of CPB, the volume of blood in the CPB circuit, approximately 1 to 1.5 liters, is currently processed for the red cell components of the blood. Yet, all the other blood components are available in this volume of blood, but are discarded. The Hemobag filters allow for whole blood reinfusion rather than just red cell reinfusion. Thus, the patient's own platelets, for example, are returned to the patient. The product is just being used clinically and we, the investigators at University of Medicine and Dentistry, New Jersey, have been asked to perform a study on our normal practice (red blood cell return as described above) compared to the whole blood return available with the Hemobag™.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborator:
Global Blood Resources, LLC